These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 30197029)

  • 21. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
    Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
    Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.
    Ibrahim DA; El-Metwally AM
    Eur J Med Chem; 2010 Mar; 45(3):1158-66. PubMed ID: 20045222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
    Yassen AS; Elshihawy HE; Said MM; Abouzid KA
    Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular modeling studies of 4,5-dihydro-1H-pyrazolo[4,3-h] quinazoline derivatives as potent CDK2/Cyclin a inhibitors using 3D-QSAR and docking.
    Ai Y; Wang ST; Sun PH; Song FJ
    Int J Mol Sci; 2010 Sep; 11(10):3705-24. PubMed ID: 21152296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.
    Park SJ; Kim E; Yoo M; Lee JY; Park CH; Hwang JY; Ha JD
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4399-4404. PubMed ID: 28827110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and molecular modeling study of certain 4-Methylbenzenesulfonamides with CDK2 inhibitory activity as anticancer and radio-sensitizing agents.
    Ghorab MM; Ragab FA; Heiba HI; Elsayed MSA; Ghorab WM
    Bioorg Chem; 2018 Oct; 80():276-287. PubMed ID: 29966874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
    Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benzimidazole-oxindole hybrids: A novel class of selective dual CDK2 and GSK-3β inhibitors of potent anticancer activity.
    Abdel-Mohsen HT; Syam YM; Abd El-Ghany MS; Abd El-Karim SS
    Arch Pharm (Weinheim); 2024 Oct; 357(10):e2300721. PubMed ID: 39041665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors.
    Lee J; Kim KH; Jeong S
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4203-5. PubMed ID: 21684737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
    Ibrahim DA; Ismail NS
    Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
    Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
    Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imidazo[1,2-c]pyrimidin-5(6H)-one as a novel core of cyclin-dependent kinase 2 inhibitors: Synthesis, activity measurement, docking, and quantum mechanical scoring.
    Ajani H; Jansa J; Köprülüoğlu C; Hobza P; Kryštof V; Lyčka A; Lepsik M
    J Mol Recognit; 2018 Sep; 31(9):e2720. PubMed ID: 29687635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6.
    Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytotoxicity, Docking Study of New Fluorinated Fused Pyrimidine Scaffold: Thermal and Microwave Irradiation Synthesis.
    Alnaja AMA; Farghaly TA; El-Zahabi HSA; Shaaban MR
    Med Chem; 2021; 17(5):501-518. PubMed ID: 31840613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and Synthesis of New CDK2 Inhibitors Containing Thiazolone and Thiazolthione Scafold with Apoptotic Activity.
    El-Sattar NEAA; Badawy EHK; AbdEl-Hady WH; Abo-Alkasem MI; Mandour AA; Ismail NSM
    Chem Pharm Bull (Tokyo); 2021; 69(1):106-117. PubMed ID: 33390512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.
    Lin T; Li J; Liu L; Li Y; Jiang H; Chen K; Xu P; Luo C; Zhou B
    Eur J Med Chem; 2021 Apr; 215():113281. PubMed ID: 33611192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.